Free Newsletter
ImClone finance chief jumps ship
ImClone System's finance-meister is jumping ship, the company announced. And no, it's not your imagination--Ana Stancic's departure will make ImClone the sixth biopharma company to lose its finance chief in recent months. There's also Pfizer (which announced its new CFO yesterday), Wyeth, AstraZeneca, Amgen, and Merck.
Stancic's departure will follow the entrance of new ImClone CEO John Johnson, who starts Monday. The company has been getting by on interim chief execs--including a three-person executive committee, which took over last year--since 2005.
- read the report from The Wall Street Journal
Related Articles:
Amgen CFO walks as challenges mount
Pfizer hires on the axe man
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: